1	
2	
3	Impact of Providing Future Cardiovascular Risk Based on Genetic Testing on Low-
4	Density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia
5	(GenTLe-FH): A Randomized Wait-list Controlled Open-Label Trial
6	
7	Short title: Impact of genetic testing on LDL-C in GenTLe-FH
8	
9	
10	Akihiro Nomura, ^{1,2} MD, PhD, Hirofumi Okada ² , MD, PhD, Atsushi Nohara ³ , MD, PhD, Masa-
11	aki Kawashiri ⁴ , MD, PhD, Masayuki Takamura ² , MD, PhD, Hayato Tada ² , MD, PhD
12	
13	¹ Innovative Clinical Research Center, Kanazawa University (iCREK), Kanazawa, Japan
14	² Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical
15	Sciences, Kanazawa, Japan
16	³ Department of Clinical Genetics, Ishikawa Prefectural Central Hospital, Kanazawa, Japan
17	⁴ Department of Internal Medicine, Kaga Medical Center, Kaga, Japan
18	
19	
20	Corresponding author:
21	Hayato Tada, MD, PhD
22	Assistant Professor
23	Department of Cardiovascular and Internal Medicine
24	Kanazawa University Graduate School of Medical Sciences
25	13-1 Takara-machi, Kanazawa, Ishikawa, 9208641 Japan
26	Phone number: +81-76-265-2254
27	E-mail: ht240z@sa3.so-net.ne.jp
28	ORCID ID: 0000-0002-3357-1809
29	
30	
31	Word count:

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 Abstract

33 Background and Aims: Familial hypercholesterolemia (FH) is an autosomal dominant 34 monogenic disease characterized by high low-density lipoprotein cholesterol (LDL-C) levels. 35 Although carrying causative FH variants is associated with coronary heart disease (CHD), it 36 remains unclear whether disclosing its associated cardiovascular risk affects outcomes in 37 patients with FH. Here, we evaluated the efficacy of providing future cardiovascular risk based 38 on genetic testing in addition to a standard FH education program.

- 39 Methods: We conducted a randomized, wait-list controlled, open-label, single-center trial. In
- 40 the intervention group, we reported a future cardiovascular risk based on the genetic testing
- 41 adding to standard FH education at week 0. In the wait-list control group, we only disseminated
- 42 standard FH education according to the guidelines at week 0; they later received a genetic
- testing-based cardiovascular risk assessment at week 24. The primary endpoint of this study 43
- 44 was the plasma LDL-C level at week 24.
- 45 **Results:** Fifty eligible patients with clinically diagnosed FH, without a history of CHD, were
- 46 allocated to the intervention group (n=24) or the wait-list control group (n=26). At week 24,
- the intervention group had a significantly greater reduction in LDL-C levels than the wait-list 47
- 48 control group (mean changes, -13.1 mg/dL vs. 6.6 mg/dL; difference, -19.7 mg/dL; 95%
- 49 confidence interval, -34 to -5.6; p=0.009). This interventional effect was consistent with FH
- 50 causative variant carriers but not with non-carriers.
- 51 Conclusions: In addition to standard FH care, providing future cardiovascular risk based on
- 52 genetic testing can further reduce plasma LDL-C levels, particularly among FH causal variant 53 carriers.
- 54
- 55 Registration: Japan Registry of Clinical Trials (jRCTs04218002).
- 56 URL: https://jrct.niph.go.jp/latest-detail/jRCTs042180027
- 57
- 58 Key words: familial hypercholesterolemia, genetic risk disclosure, genomics, coronary disease,
- 59 randomized clinical trials
- 60

61	Non-standard Abbreviations and Acronyms		
62	APOB	apolipoprotein B	
63	BMI	body mass index	
64	Bpm	beats per minutes	
65	CHD	coronary heart disease	
66	CI	confidence interval	
67	COVID-19	coronavirus disease 19	
68	CVD	cardiovascular disease	
69	FH	familial hypercholesterolemia	
70	LDL	low-density lipoprotein	
71	LDL-C	low-density lipoprotein cholesterol	
72	LDLR	low-density lipoprotein receptor	
73	LDLRAP1	low-density lipoprotein receptor adaptor protein 1	
74	PCSK9	proprotein convertase subtilisin/kexin type 9	
75	PSQ-18	Patient Satisfaction Questionnaire Short Form	

76 Introduction

77 Familial hypercholesterolemia (FH) is an autosomal dominant Mendelian disease, one 78 of the leading causes of premature coronary heart disease (CHD) along with life-long exposure to high low-density lipoprotein (LDL) cholesterolemia.¹⁻⁶ The prevalence of patients with 79 80 heterozygous FH is nearly 0.2-0.5% of the general population (1 in 200-500 individuals). Major 81 FH causative genes are LDL receptor (LDLR), proprotein convertase subtilisin/kexin type 9 82 (PCSK9), and apolipoprotein B (APOB) and LDLR adaptor protein 1 (LDLRAP1, for a particular case of autosomal recessive hypercholesterolemia). FH's clinical guidelines of FH 83 84 across the world recommend that patients with FH should be treated using lipid-lowering 85 agents at a younger age to reduce plasma LDL cholesterol (LDL-C) levels, which can prevent future episodes of CHD. Therefore, it is important to diagnose FH as early as possible.⁷ 86

87 Because FH is a monogenic disorder, genetic testing is important for a definitive diagnosis.⁸ Additionally, our previous study and other studies showed that FH-related 88 pathogenic variants are significantly associated with a higher risk of CHD,^{9,10} which strongly 89 90 suggests that genetic testing can be used for risk stratification. However, it remains unclear 91 whether FH-related genetic testing would have a potential to affects patients' outcomes beyond 92 risk stratification. Recently, Kullo et al. reported that disclosure of CHD risk estimates with 93 polygenic risk information, which consists of multiple small-effect genome-wide common 94 genetic variations, led to lower LDL-C levels than disclosure of CHD risk based on classical 95 risk factors alone.¹¹ Thus, does providing cardiovascular risk based on FH-related genetic 96 testing also have an impact on changing outcomes in patients with FH?

97 Here, we examined whether informing future cardiovascular risk based on genetic
98 testing besides conventional FH patient education leads to reduced LDL-C levels in patients
99 with FH.

100

101 Methods

102 Overall trial design

This study was a randomized, wait-list controlled, open-label, single-center trial. The 103 detailed trial protocol had been published elsewhere.⁸ In brief, we performed genetic 104 105 counseling and informed individuals about future cardiovascular risk based on patients' 106 monogenetic testing results for the intervention group. The primary outcome was the change 107 in plasma LDL-C levels at 24 weeks from the baseline. This trial was conducted in compliance 108 with the Declaration of Helsinki, Ethical Guidelines for Medical and Health Research 109 Involving Human Subjects, and all other applicable laws and guidelines in Japan. The study 110 protocol was approved by the Institutional Review Board of Kanazawa University Hospital 111 (Kanazawa, Japan) and registered in the Japan Registry of Clinical Trials (jRCTs042180027).

112

113 Participants

114 We recruited patients with clinically diagnosed FH from March 2018 to March 2020 115 and followed them up until October 2021. We enrolled participants who met all the following 116 inclusion criteria: 1) age ≥ 15 years; 2) clinically diagnosed with FH according to the Japan Atherosclerosis Society guidelines^{1,9} (if two of the three following criteria were met: [i] LDL-117 118 $C \ge 180 \text{ mg/dL}$, [ii] presence of tendon xanthomas; and [iii] family history of FH or premature coronary artery disease); and 3) never had a genetic test or had not returned genetic results 119 120 regarding FH. We also excluded participants who met any of the following exclusion criteria: 121 1) liver dysfunction (aspartate aminotransferase or alanine aminotransferase >3 times the upper 122 normal limits); 2) renal dysfunction (serum creatinine $\geq 2.0 \text{ mg/dL}$); 3) immunosuppressive 123 state; 4) active cancer; 5) history of CHD including myocardial infarction, percutaneous 124 coronary intervention or coronary artery bypass graft, or coronary artery stenosis ($\geq 75\%$)

125 previously detected by coronary angiography; or 6) females expecting to be pregnant or 126 currently pregnant. Written informed consent was obtained from all trial participants.

127

128 Screening of FH pathogenic variants

We sequenced the exons of four FH-related genes (LDLR, PCSK9, APOB, and 129 130 autosomal recessive inheritance of LDLRAP1) using Illumina MiSeq (San Diego, USA). We 131 defined variants as FH causal when they matched any of the following criteria: a) registered as 132 pathogenic/likely pathogenic in the ClinVar database; b) minor allele frequency <1% in the 133 East Asian population with i) protein-truncating variants (nonsense, canonical splice sites, or 134 frameshift) or ii) missense variants with five in silico damaging scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, MutationTaster2, LRT), all predicted as pathogenic;¹⁰ c) missense 135 136 variants reported as pathogenic in the Japanese population: PCSK9 p.Val4Ile and p.Glu32Lys;^{11,12} and d) predicted by eXome-Hidden Markov Model (XHMM) software as 137 138 copy number variations (large duplication/large deletion).¹³

139

140 Intervention and wait-list control

We randomized patients to either the intervention or the wait-list control groups with FH using an independent web-based randomization system that included a minimization algorithm balanced for age (\geq 50 years and <50 years), sex (male and female), and causative variant (positive or negative).

In the intervention group, we performed genetic counseling and informed the patients' future cardiovascular risk based on the results of their FH-related genetic testing in addition to standard FH patient education. The genetic counseling provided by a qualified physician in clinical genetics consisted of the following components: a) genetic diagnosis; b) outline of FH; c) examining the family history of hyperlipidemia/cardiovascular diseases; d) informing that the results of genetic testing could facilitate research in this field; and e) explaining the physical/mental support system in the hospital. In addition, primary cardiologists provided odds ratios of future cardiovascular risk based on the presence or absence of 1) a causal genetic variant and 2) a clinical sign (xanthomas and/or family history of FH) using the original Japanese documents.^{8,10,14} After counseling, we set sufficient time to answer the questions from the patients, confirming their level of understanding.

In the wail-list control group, we only disseminated standard FH patient education using the Japanese booklet for FH patient education according to the FH management guideline.¹ After the education session, we set the time to answer the queries from the patients. After evaluating the primary endpoint (24th week after randomization), the wait-list control group also received their genetic testing results and future cardiovascular risks via counseling.

In both groups, primary cardiologists provided the standard FH education for their 161 162 patients. Also, primary cardiologists managed LDL cholesterol levels of their patients at their 163 own discretion according to the Japanese guideline for FH 2017 (targeting LDL cholesterol 164 level of <100 mg/dL or >50% reduction compared with an untreated level for primary prevention).⁹ When adding any of lipid-lowering agents as statins, ezetimibe, or PCSK9 165 166 inhibitors, the patients and the physicians must agree with each other for the treatments that were essential to achieve the target value of LDL cholesterol level. Moreover, the number of 167 168 additional treatments were compared between the intervention and the wait-list control groups. 169 Although in-person FH education was not provided outside of the scheduled outpatient clinic 170 visits, patients in both groups could receive additional counseling and/or outpatient visit when 171 patients wanted or were afraid of genetic testing regardless of the allocated groups during and 172 after the trial.

173

174 *Outcomes*

The primary outcome was the change in plasma LDL-C levels from baseline (week 0) to week 24. Key secondary outcomes were as follows: 1) changes in plasma LDL-C levels from baseline at week 48 and 2) the Patient Satisfaction Questionnaire Short Form (PSQ-18) scales at weeks 24 and 48. We assessed these outcomes between the intervention and the waitlist control groups or among the four groups categorized by genetic testing results (FH-related causal variant, positive or negative) ([1] intervention + positive; [2] intervention + negative; [3] wait-list control + positive; and [4] wait-list control + negative).

The PSQ-18 scale evaluates patients' inner satisfaction level for the medical care they received from seven aspects.¹⁵ We used this scale because providing future cardiovascular risk based on genetic testing could create stress for the patients in terms of longer consultation time, higher medical costs, and more drug prescriptions to achieve the target cholesterol level, particularly for the intervention group. The scale values from 1 to 5 represent the lowest to highest rating for each aspect.

188

189 Statistical analysis and early termination due to the coronavirus disease 19 (COVID-19)
190 pandemic

191 We hypothesized that the estimated difference from baseline to week 24 in LDL-C levels between the intervention and the wait-list control groups would be 15 mg/dL, with a 192 193 standard deviation of 25. In the sample size calculation, 44 patients per group were required, 194 with a two-sided α of 5% and power of 80%. We then set the drop-out rate to 10% and 195 determined that approximately 100 patients with FH were required as initially planned.⁸ 196 However, we had to stop the trial enrollment in April 2020 due to the COVID-19 pandemic, 197 with a state of emergency in Japan during the enrollment period. The principal investigator and 198 sub-investigators all agreed to the decision, and we closed the trial in November 2021 after all

patients who agreed to enroll in the trial completed the protocol schedule before trialtermination.

201 We compared the outcomes between the intervention and the wait-list control groups. 202 The baseline profiles were described by mean and standard deviation, median and quantiles 203 (continuous variables), or proportion (categorical variables). In addition, we assessed the 204 primary outcome based on the intention-to-treat approach, which was compared between 205 groups using the *t*-test. Moreover, we compared the secondary endpoints between the groups 206 at each defined period using the *t*-test, Mann-Whitney U-test, Fisher's exact test, or linear or 207 logistic regression adjusted for appropriate covariates. A p-value < 0.05 was considered 208 statistically significant for the primary outcome. Statistical analyses were performed using R 209 software version 4.1.2 or above (The R Project for Statistical Computing, Vienna, Austria).

210

211 **Results**

212 Figure 1 shows the flowchart of the trial. We recruited 53 clinically diagnosed FH 213 patients without a history of cardiovascular disease from March 2018 to March 2020 and 214 followed them up until October 2021. Of these, three patients were excluded from the trial 215 because of inappropriate eligibility (n=2) and randomization violation (n=1). The remaining 216 50 eligible patients were randomly allocated to the intervention group (n=24) or the wait-list 217 control group (n=26). In the intention-to-treat principle, we included all 50 patients for further 218 analyses. The mean age of the patients was 52 ± 16 years, 58% were female, 22% had 219 hypertension, and 8% had diabetes mellitus. Regarding FH-related profiles, 76% had Achilles 220 tendon xanthomas, 60% reported a family history of FH, and the mean plasma LDL-C level 221 was 127 ± 25 mg/dL. The number of FH-related causative genetic variant positive patients was 222 34 (68%): 31 patients had causal variants at LDLR gene, 1 had causal variant (p.Glu32Lys) at 223 PCSK9 gene, and 2 had copy number variations at LDLR gene. We did not detect any causal variants at *APOB* or *LDLRAP1*. The baseline characteristics were well balanced between the intervention and the wait-list control groups (**Table 1**). Since one patient in the wait-list control group refused to follow scheduled visits and laboratory tests after randomization, the study investigators excluded the patient from the study and following outcome analyses.

- 228
- 229 Primary outcome

At week 24, the intervention group had a significantly greater reduction in plasma LDL-C levels than the wait-list control group (mean changes from baseline, -13.1 mg/dL vs. 6.6 mg/dL; between-group difference, -19.7 mg/dL; 95% confidence interval [CI], -34 to -5.6; p=0.009) (**Table 2, Figure 2**). Even when adjusted by the baseline LDL-C levels, the result was consistent (adjusted difference, -18.0 mg/dL; 95% CI, -32 to -3.8; p=0.02).

235

236 Secondary outcomes

237 After the wait-list control group also received genetic testing-based future 238 cardiovascular risk assessment at week 24, the LDL-C level in the wait-list control group was 239 certainly decreased (the within-group change from week 24 to 48 was -8.0 mg/dL). In contrast, 240 the within-group change in the intervention group from week 24 to 48 was increased by 4.3 mg/dL, that lead to diminish the effect of LDL-C reduction in the intervention group at week 241 242 48 from baseline. As a result, the difference between the two groups (between-group 243 difference) from baseline to week 48 was attenuated (0.7 vs. -2.0; between-group difference, 244 2.8; 95% CI, -26 to 31; p=0.85) (Table 2).

Figure 3 shows the LDL-C changes according to FH-related causative variant carrier status. Among variant carriers, the intervention group also had a greater plasma LDL-C level reduction than the wait-list control group at week 24 (-19.8 mg/dL vs. 2.9 mg/dL; betweengroup difference, -22.7 mg/dL; 95% CI, -40 to -5.5; p=0.02). However, we could not detect

any significant differences between the groups for non-carriers at week 24 (2.3 mg/dL vs. 12.4
mg/dL; between-group difference, -10.1 mg/dL; 95% CI, -33 to 12; p=0.39).

251 Since the physicians managed LDL cholesterol levels of their patients at their own 252 discretion according to the guideline, we investigated additional treatment regimens on top of the baseline lipid-lowering agents in both groups (Table 3). The numbers of participants 253 254 receiving add-on treatment during the study were 10 (42%) in the intervention group and 6 255 (23%) in the wait-list control group (chi-square test, p=0.26). Of note, 90% (9/10) in the 256 intervention group and 67% (4/6) in the wait-list control group of add-on lipid-lowering agents 257 were prescribed within 24 weeks from receiving genetic counseling and future cardiovascular 258 risk based on the genetic test. Moreover, the add-on treatments were conducted more frequent 259 in causative variant carrier group (14/16, 88%) than in non-carrier group (2/16, 12%).

260

261 *Patient satisfaction evaluation*

We further assessed the FH patients' satisfaction for medical care they received during the study period by the PSQ-18 scale analysis (**Figure 4**). We evaluated the score changes by seven aspects (general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience), and there were no between-group differences in each aspect except in the "general satisfaction" aspect for medical care. Notably, FH-related causal variant non-carriers in the intervention group were less satisfied with general medical care than the wait-list control group at 24 weeks.

269

270 Subgroup analysis

Table 4 shows the subgroup analysis results for the treatment differences in LDL-C
levels at week 24. There were no significant interactions in each subgroup except that age (≥50

vs. <50 years) subgroup was the only significant quantitative interaction between the
intervention and the wait-list control groups.

275

276 Discussion

This trial was the first randomized, wait-list controlled study to assess whether 277 278 disclosing the risk for future cardiovascular diseases based on genetic testing results in addition 279 to standard FH education would lead to reduced LDL-C levels in patients with FH. For the 280 primary endpoint, the intervention group showed a significantly greater reduction in plasma 281 LDL-C levels than the wait-list control group at week 24. The difference between the groups 282 was attenuated at week 48 after the wait-list control group also received future cardiovascular risk assessment based on genetic testing at week 24. On the other hand, as for patient 283 284 satisfaction evaluation by the PSQ-18, no between-group differences were found except for the 285 general satisfaction aspect of medical care. Notably, non-carriers of FH-related causal variants 286 in the intervention group were less satisfied with general medical care than those in the wait-287 list control group at 24 weeks.

288 The conclusions of this study are as follows. First, providing cardiovascular risk based 289 on genetic testing further reduced plasma LDL-C levels, in addition to standard FH care. One 290 of the reasons for the significant reduction effect could be that patients with FH may become 291 aware of the necessity of medication, leading to better adherence to medications and 292 achieving lifestyle modifications by themselves. However, there was a concern that the 293 LDL-C reduction might be derived from more intensive treatments based on the information 294 on genetic testing-based cardiovascular risk. Previous studies reported that providing genetic 295 testing results for primary physicians did not affect their practice because they thought 296 plasma lipid levels were simply sufficient to select treatment options for patients with FH and felt little need for genetic testing.^{16,17} Nevertheless, another studies demonstrated that FH 297

298 genetic counseling for patients with FH might convince them of the use of more intensified 299 lipid-lowering drugs and improve medication adherence, leading to lower LDL-C levels, irrespective of their treatment status.¹⁸⁻²⁰ Moreover, a genetic diagnosis itself could promote 300 301 the selection of more aggressive lipid-lowering drugs for primary physicians.²¹ For example, 302 the MI-GENES clinical trial, which demonstrated the effect of disclosure of CHD genetic risk 303 on LDL-C levels for patients with intermediate CHD risk, indicated that the lipid-lowering effects were derived from the initiation of statin medication.²² In this study, We did not 304 305 observe any interactions between baseline plasma LDL-C levels and the addition of lipid-306 lowering agents between weeks 0 and 24 (Figure 4). However, although non-significant, an 307 add-on lipid-lowering treatment was more frequent within 24 weeks from receiving genetic 308 counseling and future cardiovascular risk based on the genetic test (Table 3), which might 309 have contributed to the favorable result for LDL-C reduction in the intervention group. In 310 addition, genetic confirmation might help patients with FH reinforce a healthier diet and exercise behaviors.²³ These multilateral effects could affect the LDL-C levels of FH patients 311 312 without a history of cardiovascular complications. 313 Second, we observed inconsistent effects of the intervention according to the variant

314 carrier status on LDL-C levels. For FH-related causal variant carriers, the change in LDL-C 315 levels in the intervention group was greater than that in the wait-list control group at week 24, 316 although this favorable change did not occur in non-carriers. As stated above, providing a 317 "positive" genetic testing result for patients may improve adherence to lipid-lowering medication and permit access to specific treatments, such as the PCSK9 inhibitor.²⁴ 318 319 Moreover, Claassen et al. showed that patients with FH who received their genetic testing results had a higher perceived efficacy of lipid-lowering medication than those without.²⁵ In 320 321 contrast, when the FH causal variant was not identified, the negative genetic testing result might provide mental relief even for at-risk patients,²⁶ which could have a literal "negative" 322

effect on non-carrier patients. Additionally, it could cause reduced compliance or motivation
 in patients.²⁴

325 Third, although the significant LDL-C reduction was achieved after 24 weeks from 326 the disclosure of future cardiovascular risk based on genetic testing, the effect was attenuated 327 after 48 weeks of the intervention. The changes in LDL-C levels from genetic counseling 328 with providing cardiovascular risk assessment to 24 weeks were consistent in both groups (-329 13.1 mg/dL in the intervention group and -8.0 mg/dL in the wait-list control group), whereas 330 the change in LDL-C to 48 weeks was just +0.7 mg/dL despite performing some additional 331 lipid-lowering treatments on the baseline regimen. Although a long-term health behavior change was certainly challenging,^{27,28} our results implicated that the effect of our "one-time" 332 intervention in an outpatient clinic at week 0 might be effective through 6 months but could 333 334 be attenuated from then on.

335 Fourth, genetic counseling for FH did not make patients nervous overall, although non-336 carriers were less satisfied with general medical care than carriers. In general, patient 337 empowerment is a potential non-clinical benefit of genetic testing. Providing a diagnosis could 338 allow the patient to improve their understanding of the disease's clinical course, treatment options, and psychological control.^{26,29} Genetic testing sometimes ameliorates uncertainty, 339 stigma, and personal guilt.^{30,31} However, it could be valid only in FH patients with positive 340 341 genetic testing, not in those with negative genetic testing. Patients sometimes undergo genetic 342 testing because they want to confirm whether they are negative. Clinically diagnosed patients 343 with FH are at a higher risk for cardiovascular disease than patients without FH, regardless of 344 the causative variant carrier status. However, when we provide variant-negative patients with 345 less CHD risk than variant-positive FH patients, they might misunderstand the information, 346 become unexpectedly reassured, and decrease their adherence and lifestyle modification. Care 347 might be taken with these "non-carriers" to provide the current FH education strategy with

future cardiovascular risk assessment based on the variant-negative genetic testing results. This is because the counseling provided in this study might potentially provide misinterpretation and less satisfaction for medical care to "non-carriers". Therefore, alternative counseling strategies may be needed for patients with variant-negative FH.

The strength of this study was that it was a randomized trial to demonstrate the efficacy 352 353 of disclosing future cardiovascular disease risk assessment based on genetic testing results in 354 addition to standard FH education for FH patients without a history of cardiovascular disease. 355 The most important limitation of this study was that while we originally planned to enroll approximately 100 FH patients in this study,⁸ we halted enrollment due to the COVID-19 356 357 pandemic and closed recruitment before completing the pre-specified protocol schedule. Although the effect difference on LDL-C was larger than expected and we demonstrated the 358 359 efficacy of the intervention on LDL-C levels, this unique situation needs to be considered with 360 caution for clinical application of our findings. In addition, in terms of LDL-C levels, the mean 361 LDL-C levels at 48 weeks were still >100 mg/dL in both groups, which was above the 362 recommended lipid control threshold (<100 mg/dL) for FH patients as primary prevention. 363 Although clarifying cardiovascular risk for both FH patients and primary physicians could improve the treatment quality,³² achieving the target LDL-C level (<100 mg/dL) has still been 364 a challenging goal, as the CASCADE-FH registry reported.³³ Although this study's median 365 366 LDL-C level was lower than that from the registry, we need to focus on the target cholesterol 367 level to reduce the future cardiovascular risk for patients with FH as much as possible. Furthermore, we could not assessed patients' medication adherence except patient-reported 368 369 drug non-compliance that might affect the results.

In conclusion, in addition to standard FH care, providing cardiovascular risk assessment
 based on genetic testing further reduced plasma LDL-C levels further, particularly among

patients with FH causal variants carriers. Meanwhile, we might be careful with the non-carriers
to provide this risk disclosure strategy based on the variant-negative genetic testing results.

374

375 Acknowledgements

We are very thankful to all the participants and staff regarding this trial. We also express our gratitude to Mitsuyo Kusajima, Emi Tamukai, Ryogo Shimizu, Asako Kanadu, and Rika Miyashita as clinical research coordinators; Kenichi Yoshimura, Hideki Ishikawa for randomization and statistical assistance; Yasuhiko Imai, and Jia Yu for clinical data management; and Toshinori Murayama, chairman of the Innovative Clinical Research Center, Kanazawa University for supporting our clinical trial.

382

383 Funding

This trial was supported by a Clinical Research Grant from Kanazawa University Hospital, JSPS KAKENHI (18K08064, 19K08553, 20H03927), the Astellas Foundation for Research on Metabolic Disorders, the ONO Medical Research Foundation, the Ministry of Health, Labour and Welfare of Japan (Research Grant for Rare and Intractable Diseases), and the Japanese Circulation Society (Project for Genome Analysis in Cardiovascular Diseases).

390 Conflict of interest

391 The authors have no conflict of interest to disclose.

392

Data availability statement

The data in this trial are available from the corresponding author upon reasonablerequest.

396 **References**

- Harada-Shiba M, Arai H, Oikawa S, *et al.* Guidelines for the management of familial
 hypercholesterolemia. *J Atheroscler Thromb* 2012;**19**:1043-1060. doi:
- 399 2. Gidding SS, Champagne MA, de Ferranti SD, *et al.* The Agenda for Familial
- 400 Hypercholesterolemia: A Scientific Statement From the American Heart Association.
- 401 *Circulation* 2015;**132**:2167-2192. doi: 10.1161/CIR.00000000000297
- 402 3. Watts GF, Gidding S, Wierzbicki AS, *et al.* Integrated guidance on the care of
- 403 familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol
- 404 2014;**171**:309-325. doi: 10.1016/j.ijcard.2013.11.025
- 405 4. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial
- 406 hypercholesterolaemia is underdiagnosed and undertreated in the general population:
- 407 guidance for clinicians to prevent coronary heart disease: consensus statement of the
- 408 European Atherosclerosis Society. *Eur Heart J* 2013;**34**:3478-3490a. doi:
- 409 10.1093/eurheartj/eht273
- 410 5. Mabuchi H, Nohara A, Noguchi T, *et al.* Molecular genetic epidemiology of
- 411 homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis
- 412 2011;**214**:404-407. doi: 10.1016/j.atherosclerosis.2010.11.005
- 413 6. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial
- 414 hypercholesterolaemia: a long term cohort study. *BMJ* 2008;**337**:a2423. doi:
- 415 10.1136/bmj.a2423
- 416 7. Teramoto T, Kobayashi M, Tasaki H, et al. Efficacy and Safety of Alirocumab in
- 417 Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High
- 418 Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins-
- 419 ODYSSEY JAPAN Randomized Controlled Trial. *Circ J* 2016;**80**:1980-1987. doi:
- 420 10.1253/circj.CJ-16-0387
- 421 8. Nomura A, Tada H, Okada H, et al. Impact of genetic testing on low-density
- 422 lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a
- 423 randomised waiting list controlled open-label study protocol. *BMJ Open* 2018;8:e023636.
- 424 doi: 10.1136/bmjopen-2018-023636
- 425 9. Harada-Shiba M, Arai H, Ishigaki Y, *et al.* Guidelines for Diagnosis and Treatment of
- 426 Familial Hypercholesterolemia 2017. J Atheroscler Thromb 2018;25:751-770. doi:
- 427 10.5551/jat.CR003

428	10. Khera A	V, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of
429	Sequencing Fan	nilial Hypercholesterolemia Genes in Patients With Severe
430	Hypercholester	olemia. J Am Coll Cardiol 2016;67:2578-2589. doi:
431	10.1016/j.jacc.2	016.03.520
432	11. Mabuch	H, Nohara A, Noguchi T, et al. Genotypic and phenotypic features in
433	homozygous far	nilial hypercholesterolemia caused by proprotein convertase subtilisin/kexin
434	type 9 (PCSK9)	gain-of-function mutation. Atherosclerosis 2014;236:54-61. doi:
435	10.1016/j.athero	sclerosis.2014.06.005
436	12. Ohta N,	Hori M, Takahashi A, et al. Proprotein convertase subtilisin/kexin 9 V4I
437	variant with LD	LR mutations modifies the phenotype of familial hypercholesterolemia. J
438	Clin Lipidol 201	6; 10 :547-555 e545. doi: 10.1016/j.jacl.2015.12.024
439	13. Fromer I	A, Moran JL, Chambert K, et al. Discovery and statistical genotyping of
440	copy-number va	riation from whole-exome sequencing depth. Am J Hum Genet 2012;91:597-
441	607. doi: 10.101	6/j.ajhg.2012.08.005
442	14. Tada H,	Kawashiri MA, Nohara A, et al. Impact of clinical signs and genetic
443	diagnosis of fan	nilial hypercholesterolaemia on the prevalence of coronary artery disease in
444	patients with sev	vere hypercholesterolaemia. Eur Heart J 2017. doi: 10.1093/eurheartj/ehx004
445	15. Marshall	G, Hays R. The Patient Satisfaction Questionnaire
446	Short Form (PS	Q-18). Santa Monica, CA: RAND Corporation; 1994. p7865.
447	16. Will CM	, Armstrong D, Marteau TM. Genetic unexceptionalism: clinician accounts
448	of genetic testin	g for familial hypercholesterolaemia. Soc Sci Med 2010;71:910-917. doi:
449	10.1016/j.socsci	med.2010.05.018
450	17. Lerner B	, Marshall N, Oishi S, et al. The value of genetic testing: beyond clinical
451	utility. Genet M	ed 2017; 19 :763-771. doi: 10.1038/gim.2016.186
452	18. Umans-l	Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ.
453	Review of first :	5 years of screening for familial hypercholesterolaemia in the Netherlands.
454	Lancet 2001; 35 '	7:165-168. doi: 10.1016/S0140-6736(00)03587-X
455	19. Leren Tl	P. Cascade genetic screening for familial hypercholesterolemia. Clin Genet
456	2004; 66 :483-48	7. doi: 10.1111/j.1399-0004.2004.00320.x
457	20. Sturm A	C, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial
458	Hypercholester	Demia: JACC Scientific Expert Panel. J Am Coll Cardiol 2018; 72 :662-680.
459	doi: 10.1016/j.ja	ucc.2018.05.044

- 460 21. Paynter NP, Ridker PM, Chasman DI. Are Genetic Tests for Atherosclerosis Ready
- 461 for Routine Clinical Use? *Circ Res* 2016;**118**:607-619. doi:
- 462 10.1161/CIRCRESAHA.115.306360

463 22. Kullo IJ, Jouni H, Austin EE, et al. Incorporating a Genetic Risk Score Into Coronary

- 464 Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the
- 465 MI-GENES Clinical Trial). *Circulation* 2016;**133**:1181-1188. doi:
- 466 10.1161/CIRCULATIONAHA.115.020109
- 467 23. Hagger MS, Hardcastle SJ, Hingley C, et al. Predicting Self-Management Behaviors
- 468 in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of
- 469 Beliefs About Illnesses and Beliefs About Behaviors. Int J Behav Med 2016;23:282-294. doi:
- 470 10.1007/s12529-015-9531-x
- 471 24. Brown EE, Sturm AC, Cuchel M, et al. Genetic testing in dyslipidemia: A scientific
- 472 statement from the National Lipid Association. *J Clin Lipidol* 2020;**14**:398-413. doi:
- 473 10.1016/j.jacl.2020.04.011
- 474 25. Claassen L, Henneman L, van der Weijden T, Marteau TM, Timmermans DR. Being
- 475 at risk for cardiovascular disease: perceptions and preventive behavior in people with and
- 476 without a known genetic predisposition. *Psychol Health Med* 2012;**17**:511-521. doi:
- 477 10.1080/13548506.2011.644246
- 478 26. Severin F, Borry P, Cornel MC, et al. Points to consider for prioritizing clinical
- 479 genetic testing services: a European consensus process oriented at accountability for
- 480 reasonableness. *Eur J Hum Genet* 2015;**23**:729-735. doi: 10.1038/ejhg.2014.190
- 481 27. Middleton KR, Anton SD, Perri MG. Long-Term Adherence to Health Behavior
 482 Change. *Am J Lifestyle Med* 2013;**7**:395-404. doi: 10.1177/1559827613488867
- 483 28. Bouton ME. Why behavior change is difficult to sustain. *Prev Med* 2014;**68**:29-36.
- 484 doi: 10.1016/j.ypmed.2014.06.010
- 485 29. Berberich AJ, Hegele RA. The role of genetic testing in dyslipidaemia. *Pathology*486 2019;**51**:184-192. doi: 10.1016/j.pathol.2018.10.014
- 487 30. Senior V, Smith JA, Michie S, Marteau TM. Making sense of risk: an interpretative
- 488 phenomenological analysis of vulnerability to heart disease. J Health Psychol 2002;7:157-
- 489 168. doi: 10.1177/1359105302007002455
- 490 31. Weiner K, Durrington PN. Patients' understandings and experiences of familial
- 491 hypercholesterolemia. *Community Genet* 2008;**11**:273-282. doi: 10.1159/000121398

- 492 32. Jones LK, Sturm AC, Seaton TL, et al. Barriers, facilitators, and solutions to familial
- 493 hypercholesterolemia treatment. *PLoS One* 2020;**15**:e0244193. doi:
- 494 10.1371/journal.pone.0244193
- 495 33. deGoma EM, Ahmad ZS, O'Brien EC, et al. Treatment Gaps in Adults With
- 496 Heterozygous Familial Hypercholesterolemia in the United States: Data From the
- 497 CASCADE-FH Registry. *Circ Cardiovasc Genet* 2016;**9**:240-249. doi:
- 498 10.1161/CIRCGENETICS.116.001381
- 499

500 Figure legends.

501 Figure 1. Trial flowchart.

502 We enrolled 53 patients with clinically diagnosed FH and no prior coronary artery disease. Of

those, 50 eligible FH patients were randomly allocated to the intervention group (24 patients

504 receiving conventional FH education and future cardiovascular risk assessment based on

505 genetic testing) or the wait-list control group (26 patients receiving only conventional FH

506 education). We followed the two groups for up to 48 weeks and performed an intention-to-

507 treat analysis. The primary endpoint was the change in LDL-C levels from baseline at week

508 24. Because we handled the wait-list control group as a wait-list group, we also provided

509 future cardiovascular risk assessment based on genetic testing after evaluating the primary

- 510 endpoint at week 24.
- 511

512 Figure 2. Low-density lipoprotein cholesterol changes from baseline.

513 Regarding the primary endpoint at week 24, the intervention group had a significantly greater

reduction in plasma LDL-C level than the wait-list control group. After the wait-list control

515 group also received genetic testing-based future cardiovascular risk assessment at week 24,

the difference between the two groups was attenuated at week 48. *:p<0.05. Error bars

- 517 indicated the standard error.
- 518

519 Figure 3. Low-density lipoprotein cholesterol changes from baseline by FH-related 520 causative variant carrier status with additional treatment information.

A. Variant carriers (n=34). **B.** Non-carriers (n=16). Treatment icons (statin or ezetimibe, statin and ezetimibe, or PCSK9 inhibitor) were placed at the time of each additional medication. Among variant carriers, the intervention group also had a greater plasma LDL-C level reduction than the wait-list control group at week 24. However, we could not detect any apparent differences between the groups for non-carriers. Error bars indicated standard errors 526

527 Figure 4. Changes in patient satisfaction questionnaire scale scores by groups.

There were no between-group differences except in the "general satisfaction" aspect of medical care. According to the general satisfaction scale results, variant non-carriers in the intervention group were less satisfied with general medical care than the wait-list control group at 24 weeks. *:p<0.05. Error bars indicated the standard error.

Table 1. Baseline characteristics. 532

	Total	Intervention	Wait-list control
N	50	24	26
Age, years	52 ± 16	54 ± 15	50 ± 17
Female, n (%)	29 (58)	13 (54)	16 (62)
Body weight, kg	64.0 [55-69]	64.0 [55-68]	64.1 [55-71]
BMI, kg/m ²	23.4 [22-27]	23.7 [21-28]	23.0 [22-26]
Systolic blood pressure, mmHg	116 ± 16	116 ± 14	117 ± 17
Diastolic blood pressure, mmHg	70 ± 10	70 ± 10	70 ± 11
Heart rate, bpm	67 ± 11	66 ± 13	69 ± 9
Comorbidities, n (%)			
Hypertension	11 (22)	6 (25)	5 (19)
Diabetes mellitus	4 (8)	1 (4)	3 (12)
Current smoking	5 (10)	2 (8)	3 (12)
FH-related profile, n (%)			
Achilles tendon xanthomas	38 (76)	19 (79)	19 (73)
Family history of FH	30 (60)	12 (50)	18 (69)
Lipid-lowering agents at baseline, n (%)			
Statins	48 (96)	23 (96)	25 (96)
Ezetimibe	34 (68)	17 (71)	17 (65)
PCSK9 inhibitors	1 (2)	0	1 (4)
Genetic variants, n (%)			
Positive	34 (68)	17 (71)	17 (65)
At LDLR gene	31	15	16
At PCSK9 gene	1	1	0
At APOB gene	0	0	0
At LDLRAP1 gene (AR inheritance)	0	0	0
Copy number variations (at LDLR gene)	2	1	1
Negative	16 (32)	7 (29)	9 (35)
Lipid profiles			
Total cholesterol, mg/dL	205 ± 31	209 ± 33	200 ± 29
Triglycerides, mg/dL	100 ± 65	112 ± 74	90 ± 55
High-density lipoprotein cholesterol, mg/dL	59 ± 13	57 ± 12	60 ± 14
Low-density lipoprotein cholesterol, mg/dL	127 ± 25	133 ± 28	121 ± 21
PSQ-18 scale aspect			
General satisfaction	3.98 ± 0.62	3.96 ± 0.67	4.00 ± 0.58
Technical quality	3.99 ± 0.52	3.89 ± 0.59	4.09 ± 0.45
Interpersonal manner	4.09 ± 0.57	4.08 ± 0.62	4.10 ± 0.53
Communication	4.34 ± 0.41	4.38 ± 0.45	4.31 ± 0.38
Financial aspects	3.30 ± 0.68	3.21 ± 0.85	3.39 ± 0.48
Time spent with a doctor	3.74 ± 0.61	3.85 ± 0.65	3.64 ± 0.56
Accessibility and convenience	3.71 ± 0.49	3.73 ± 0.49	3.68 ± 0.49

- 533 Continuous values were expressed as mean \pm standard deviation or median (interquartile range).
- 534 Abbreviations: AR, autosomal recessive; BMI, body mass index; bpm, beats per minutes; FH,
- 535 familial hypercholesterolemia; LDLR, low-density lipoprotein receptor; PCSK9, proprotein
- 536 convertase subtilisin/kexin type 9; PSQ-18, Patient Satisfaction Questionnaire Short Form.

Table 2. Within-group changes and between-group differences of LDL cholesterol 538

539 levels.

	week 0 (baseline) vs. week 24	week 24 vs. week 48	week 0 (baseline) vs. week 48
1. All participants			
Within-group changes			
Intervention group			
LDL-C, mean change (SE)	-13.1 (6.2)	4.3 (2.6)	0.7 (11.3)
Wait-list control group			
LDL-C, mean change (SE)	6.6 (6.7)	-8.0 (7.0)	-2.0 (9.0)
Between-group differences*			
	-19.7	12.3	2.7
LDL-C, mean change [95% CI]	[-33.8 to -5.6]	[-2.0 to 26.6]	[-25.6 to 31.1]
-	p=0.009**	p=0.10	p=0.85
2. Causative variant positive Within-group changes			
I DL-C mean change (SE)	-198(66)	60(30)	-0.1(15.6)
Wait-list control group	-17.8 (0.0)	0.0 (3.0)	-0.1 (15.0)
LDL-C mean change (SE)	29(56)	-96(115)	-77(130)
Between-groun differences*	2.9 (0.0)	9.0 (11.5)	/./ (15.0)
Detween group unterences	-22.7	15 5	7.6
LDL-C, mean change [95% CI]	[-39.9 to -5.5]	[-5.7 to 36.7]	[-33.3 to 48.5]
	p=0.02**	p=0.16	p=0.72
3. Causative variant negative Within-group changes			
I DL-C mean change (SE)	23(65)	0.5(4.9)	28(91)
Wait-list control group	2.3 (0.5)	0.3 (4.7)	2.0 (9.1)
LDL-C mean change (SE)	124(87)	-57(51)	68(112)
Between-groun differences*	12.1 (0.7)	5.7 (5.1)	0.0 (11.2)
Zerreen Stoup unterences	-10.1	62	-39
LDL-C, mean change [95% CI]	[-32.5 to 12.3]	[-8.0 to 20.3]	[-33.4 to 25.6]
	p=0.39	p=0.41	p=0.80

540

541 *: P values were calculated comparing the intervention group with the wait-list control group

using the *t*-test. **: p<0.05. 542

	Intervention	Wait-list control	
	(n=24)	(n=26)	
Total number of add-on treatment	10 (42%)	6 (23%)	
Add-on timing			
Week 0 to week 16	9 (9/10, 90%)	2 (2/6, 33%)	
At week 0	8	2	
At week 8	1	0	
At week 16	0	0	
Week 24 to week 40	1 (1/10, 10%)	4 (4/6, 67%)	
At week 24	0	3	
At week 32	0	1	
At week 40	1	0	
Causative variant			
Carrier subgroup	9 (9/10, 90%)	5 (5/6, 83%)	
Non-carrier subgroup	1 (1/10, 10%)	1 (1/6, 17%)	
Add-on treatment regimen			
Statin / ezetimibe	9 (9/10, 90%)	3 (3/6, 50%)	
PCSK9 inhibitor	1 (1/10, 10%)	3 (3/6, 50%)	

Table 3. Add-on treatment regimens by primary physicians during study period. 544

545

PCSK9, proprotein convertase subtilisin/kexin type 9. 546

547 Table 4. Treatment differences in low-density lipoprotein cholesterol changes at week 24

	Intervention	Wait-list control	Difference (95% CI)	P interaction
Age ≥50 (n=26)	-5.2	1.4	-6.6 [-20 to 7.0]	0.038
Age <50 (n=24)	-23.3	13.4	-36.7 [-62 to -11]	
Male (n=21)	-12.2	-0.4	-11.8 [-33 to 9.7]	0.41
Female (n=29)	-13.8	10.4	-24.2 [-43 to -5.0]	
BMI ≥25 (n=15)	-19.1	2.3	-21.4 [-48 to 5.1]	0.88
BMI <25 (n=35)	-10.4	8.6	-19.0 [-36 to -2.0]	
Hypertension+ (n=11)	-6.6	-0.6	-6.0 [-28 to 16]	0.30
Hypertension- (n=39)	-15.4	8.6	-24.0 [-41 to -6.7]	
Xanthomas+ (n=39)	-9.5	7.7	-17.2 [-33 to -1.1]	0.51
Xanthomas- (n=11)	-25.9	3.0	-28.9 [-58 to 0.3]	
Family history of FH+ (n=30)	-12.7	8.9	-21.5 [-39 to -3.6]	0.71
Family history of FH- (n=20)	-13.5	2.4	-15.9 [-40 to 8.2]	
Causative variant positive (n=34)	-19.8	2.9	-22.7 [-40 to -9.6]	0.40
Causative variant negative (n=16)	2.3	12.4	-10.1 [-33 to 12]	
Baseline LDL-C \geq 130 (n=21)	-25.8	3.4	-29.2 [-54 to -4.7]	0.24
Baseline LDL-C <130 (n=29)	-3.3	9.1	-12.4 [-27 to 2.6]	
Adding lipid-lowering agents at week 0 to 16+ (n=11)	-20.4	5.4	-25.8 [-80 to 28]	0.72
Adding lipid-lowering agents at week 0 to 16- (n=39)	-9.2	6.7	-15.9 [-32 to 0.1]	

548 between the intervention and the wait-list control groups by patient subgroups.

549

550 Abbreviations: BMI, body mass index; CI, confidence interval; FH, familial 551 hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol.

552 Figure 1. Trial flowchart.



553





- 557 Figure 3. Low-density lipoprotein cholesterol changes from baseline by FH-related causative
- variant carrier status with additional treatment information.





Figure 4. Changes in patient satisfaction questionnaire scale scores by groups.